Preferred Label : oxazoles;

MeSH definition : Five-membered heterocyclic ring structures containing an oxygen in the 1-position and a nitrogen in the 3-position, in distinction from ISOXAZOLES where they are at the 1,2 positions.;

MeSH synonym : Oxazole;

MeSH hyponym : munchnones; 1,3-Oxazolium-5-Oxides; 1,3 Oxazolium 5 Oxides;

MeSH CAS label : 1,3-Oxazole;

MeSH annotation : includes oxazolines, oxazolidines;

Is substance : O;

Details


Main resources

You can consult :

Five-membered heterocyclic ring structures containing an oxygen in the 1-position and a nitrogen in the 3-position, in distinction from ISOXAZOLES where they are at the 1,2 positions.

https://www.ema.europa.eu/en/medicines/human/EPAR/tukysa
2021
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
oxazoles
oxazoles
pyridines
pyridines
quinazolines
quinazolines
antineoplastic agents
antineoplastic agents
protein kinase inhibitors
protein kinase inhibitors
tucatinib
receptor, erbB-2
risk management
product surveillance, postmarketing
breast neoplasms
neoplasm metastasis
HER2-positive metastatic breast cancer
antineoplastic combined chemotherapy protocols
Capecitabine/Trastuzumab/Tucatinib Regimen
administration, oral
adult
aged
continuity of patient care
drug interactions
pregnancy
breast feeding
survival analysis
drug evaluation, preclinical
tucatinib
tucatinib
HER2-Positive Breast Carcinoma
Tyrosine Kinase Inhibitors

---
https://ansm.sante.fr/tableau-marr/delamanide
2021
false
false
false
France
French
risk management
delamanid
administration, oral
delamanid
patient education handout
pregnancy
breast feeding
delamanid
long qt syndrome
pharmacovigilance note
drug resistance, bacterial
antibiotics, antitubercular
antibiotics, antitubercular
OPC-67683
OPC-67683
nitroimidazoles
oxazoles
nitroimidazoles
oxazoles

---
https://www.has-sante.fr/jcms/p_3273459/fr/tukysa-tucatinib
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
tucatinib
antineoplastic agents
protein kinase inhibitors
tucatinib
antineoplastic combined chemotherapy protocols
Trastuzumab
Capecitabine
Capecitabine/Trastuzumab/Tucatinib Regimen
adult
breast neoplasms
HER2-Positive Breast Carcinoma
evaluation of the transparency committee
oxazoles
pyridines
quinazolines

---
https://www.has-sante.fr/jcms/p_3269474/fr/deltyba-delamanid
2021
false
false
false
France
evaluation of the transparency committee
delamanid
OPC-67683
nitroimidazoles
oxazoles
tuberculosis, pulmonary
delamanid
treatment outcome
insurance, health, reimbursement
administration, oral
antibiotics, antitubercular
tuberculosis, multidrug-resistant
adult
adolescent
child

---
https://ansm.sante.fr/tableau-atu-rtu/tucatinib-50-mg-comprime-pellicule
2021
false
false
false
France
French
administration, oral
summary of product characteristics
package leaflet
guidelines for drug use
antineoplastic agents
protein kinase inhibitors
tucatinib
Tucatinib
Tucatinib
oxazoles
pyridines
quinazolines
antineoplastic combined chemotherapy protocols
adult
breast neoplasms
Trastuzumab
Capecitabine
Capecitabine/Trastuzumab/Tucatinib Regimen
neoplasm metastasis
receptor, erbB-2
tucatinib
tucatinib
HER2-Positive Breast Carcinoma
oxazoles
pyridines
quinazolines

---
https://www.has-sante.fr/jcms/p_3120940/fr/deltyba
2019
false
false
false
France
administration, oral
insurance, health, reimbursement
treatment outcome
delamanid
delamanid
antibiotics, antitubercular
tuberculosis, multidrug-resistant
tuberculosis, pulmonary
adult
evaluation of the transparency committee
OPC-67683
nitroimidazoles
oxazoles

---
http://www.has-sante.fr/portail/jcms/c_2581332/fr/sivextro
2015
false
false
false
France
French
treatment outcome
tedizolid phosphate
tedizolid phosphate
anti-bacterial agents
anti-bacterial agents
adult
aged
acute disease
skin diseases, bacterial
soft tissue infections
cellulitis
abscess
wound infection
Skin Abscess
administration, oral
infusions, intravenous
staphylococcal skin infections
Methicillin-Resistant staphylococcus aureus
prodrugs
evaluation of the transparency committee
methicillin resistance
tedizolid
guidelines for drug use
Methicillin resistant Staphylococcus aureus infection (disorder)
antibiotic therapy
oxazoles
organophosphates
oxazoles
organophosphates

---
https://www.ema.europa.eu/medicines/human/EPAR/Sivextro
2015
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
tedizolid phosphate
tedizolid phosphate
drug approval
europe
anti-bacterial agents
anti-bacterial agents
adult
aged
acute disease
skin diseases, bacterial
soft tissue infections
cellulitis
abscess
wound infection
Skin Abscess
administration, oral
infusions, intravenous
staphylococcal skin infections
Methicillin-Resistant staphylococcus aureus
product surveillance, postmarketing
drug interactions
pregnancy
breast feeding
prodrugs
oxazolidinones
protein synthesis inhibitors
drug evaluation, preclinical
tedizolid
Methicillin resistant Staphylococcus aureus infection (disorder)
antibiotic therapy
oxazoles
organophosphates
oxazoles
organophosphates

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=67869725
2009
France
French
oxazoles
antihypertensive agents
adrenergic alpha-agonists
summary of product characteristics
package leaflet

---
Nous contacter.
26/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.